Northwest Biotherapeutics, Inc. (NWBO)
Northwest Biotherapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Bethesda, MD, US. The stock last traded at $0.19, down 1.58% on the session, giving a market capitalisation of $307.3M. On trailing twelve-month figures it carries a trailing P/E of -6.13, a net margin of -2931.7%. Its beta of -0.62 implies it has historically moved less than the broad market.
Northwest Biotherapeutics, Inc. (NWBO) is a biotechnology firm that creates personalized immune-based treatments for various cancers, operating both within the United States and internationally. Their product pipeline relies on DCVax, a proprietary technology platform. This platform harnesses a patient's own activated dendritic cells to stimulate their immune system to combat cancerous cells. The company's leading therapeutic candidate, DCVax-L, has successfully completed Phase III clinical trials targeting Glioblastoma multiforme, an aggressive form of brain cancer. Additionally, Northwest Biotherapeutics is progressing DCVax-Direct through Phase I/II clinical studies, focusing on the treatment of inoperable solid tumors. Founded in 1996, the company's headquarters are situated in Bethesda, Maryland.
Northwest Biotherapeutics, Inc. is most often compared with the following Healthcare names: